Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma $(HCC)$, with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.